Xu Ziwei, Wang Huafang
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Immunol. 2025 Jan 7;15:1525244. doi: 10.3389/fimmu.2024.1525244. eCollection 2024.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) constitutes a critical therapeutic approach for patients with malignant hematological disorders. Nevertheless, acute graft-versus-host disease (GVHD), one of the most prevalent complications associated with HSCT, remains a leading contributor to non-relapse mortality. In recent years, there has been an increasing focus on the interplay between chemokines and their receptors in the context of acute GVHD. Chemokines exert substantial effects across various pathological conditions, including autoimmune diseases, inflammatory processes, tumorigenesis, and metastatic dissemination. In this review, we aim to elucidate the role of chemokines in the pathogenesis of acute GVHD and further understand their potential as diagnostic biomarkers. We also present both preclinical and clinical insights into the application of chemokines in preventing and treating acute GVHD. The objective of this review is to offer novel perspectives on the clinical diagnosis and management strategies for acute GVHD.
异基因造血干细胞移植（allo-HSCT）是恶性血液系统疾病患者的关键治疗方法。然而，急性移植物抗宿主病（GVHD）作为HSCT最常见的并发症之一，仍然是导致非复发死亡率的主要因素。近年来，在急性GVHD背景下，趋化因子及其受体之间的相互作用受到越来越多的关注。趋化因子在各种病理状况中发挥着重要作用，包括自身免疫性疾病、炎症过程、肿瘤发生和转移扩散。在本综述中，我们旨在阐明趋化因子在急性GVHD发病机制中的作用，并进一步了解它们作为诊断生物标志物的潜力。我们还介绍了趋化因子在预防和治疗急性GVHD方面的临床前和临床见解。本综述的目的是为急性GVHD的临床诊断和管理策略提供新的视角。
